Key result
Factor V Leiden and 20210 A prothrombin mutations are not major risk factors for myocardial infarction or stroke unless accompanied by classical risk factors.
Genetic thrombophilia mutations (Factor V Leiden, prothrombin 20210A) require classical risk factors to significantly increase the risk of arterial thrombosis, and MTHFR is not a major risk factor for venous thrombosis.
Answers are grounded in this paper and cite their sources.
Classical risks should guide MI/stroke prevention over routine thrombophilia testing; leaves open synergistic effects needing prospective confirmation.
Thrombophilia is now considered a multicausal disease, with an interplay of acquired and genetic risk factors. Recent studies have shown that patients with the 20210 A prothrombin mutation display remarkably similar characteristics compared with patients with Factor V Leiden mutation. It is evident that neither the Factor V Leiden mutation nor the 20210 A prothrombin mutation is a major risk factor for myocardial infarction or stroke, unless accompanied by other classical risk factors, including diabetes mellitus, hypertension and smoking. Finally, the homozygous form of the thermolabile methylenetetrahydrofolate reductase gene, although leading to elevated homocysteine levels, seems not to represent a genetic risk factor for venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Huisman et al. (1999) conducted a review in Thrombophilia. Genetic risk factors (Factor V Leiden, 20210 A prothrombin mutation, MTHFR) was evaluated. Factor V Leiden and 20210 A prothrombin mutations are not major risk factors for myocardial infarction or stroke unless accompanied by classical risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: